v3.25.1
Revenue (Details Narrative) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Disaggregation of Revenue [Line Items]    
Revenues $ 93,864 $ 7,617,174
License [Member] | Antares Pharma [Member]    
Disaggregation of Revenue [Line Items]    
Revenues   67,000
Verity License Agreement [Member]    
Disaggregation of Revenue [Line Items]    
Royalty Income, Nonoperating $ 94,000 51,000
Verity License Agreement [Member] | License [Member]    
Disaggregation of Revenue [Line Items]    
Revenues   $ 7,500,000
Major Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Concentration Risk, Percentage 10.00%  
One Major Customer [Member] | Revenue Benchmark [Member] | Customer Concentration Risk [Member]    
Disaggregation of Revenue [Line Items]    
Concentration Risk, Percentage   99.00%